ESMO 2023 | Genitourinary cancer highlights at ESMO 2023

Roberto Iacovelli, MD, Agostino Gemelli University Policlinic, Rome, Italy, provides his highlights in genitourinary cancer at the European Society for Medical Oncology (ESMO) 2023 Congress, including very promising results from the EV-302 (NCT04223856) in urothelial cancer. Whilst there have been positive findings from trials assessing belzutifan in kidney cancer, more research is needed to properly sequence current therapies, especially in the second-line setting. This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.